Numerate and Takeda Enter Agreement to Generate Novel Clinical Candidates Using AI-Driven Drug Discovery

Numerate, Inc., a computational drug design company applying artificial intelligence (AI) at cloud scale to transform small molecule drug discovery, announced the formation of a multi-year agreement with Takeda Pharmaceutical Company Limited (TSE: 4502) under which Numerate will identify and deliver multiple clinical candidates.

Under the agreement, Numerate will drive discovery programs aimed at identifying clinical candidates for use in Takeda’s core therapeutic areas: oncology, gastroenterology, and central nervous system disorders. The projects will rely on Numerate leveraging its AI-driven platform, from hit finding and expansion through lead design/optimization and ADME (absorption, distribution, metabolism and excretion)/toxicity modeling.

“This is an ideal arrangement for Numerate because our team will be working largely independently while having the opportunity to leverage Takeda’s global experience, therapeutic area insights, and unique R&D capabilities,” said Guido Lanza, President and CEO of Numerate. “We expect to produce multiple clinical candidates, while also continuing to refine, validate and expand our proprietary AI-driven platform as we work across a broad range of target types and drug design challenges.”

Financial terms of the current agreement were not disclosed, but include a combination of milestone payments and royalties that reflect the value of the clinical candidates being delivered.

“We are excited to partner with Numerate. Numerate has established an impressive track record of leveraging their AI platform to overcome drug design challenges, both for its own pipeline and in pharma/biotech collaborations,” said David Weitz, Head of Takeda California and Global Research Externalization. “By having Numerate select projects that align with Takeda’s strategy we expect the partnership to yield multiple assets that Takeda can develop into truly transformative medicines for patients.”

Numerate and Servier Establish Collaboration to Advance First-in-Class Ryanodine Receptor 2 Candidates for Cardiovascular Diseases

Numerate, Inc., a computational drug design company applying artificial intelligence (AI) at cloud scale to transform small molecule drug discovery, and Servier, an independent international pharmaceutical company, today announced a collaboration to pursue the design of small molecule modulators of ryanodine receptor 2 (RyR2), a target identified as physiologically important in cardiovascular diseases, but whose drug-ability has proven highly challenging. This collaboration could lead to potential first-in-class therapies for cardiovascular diseases, including heart failure and arrhythmias.

Ryanodine receptor dysfunction is known to be involved in the defects in calcium handling associated with cardiovascular diseases. The design of novel ryanodine receptor modulators remains challenging to address with traditional drug discovery methods, largely because of the complexity of the underlying biology.

Numerate’s disruptive, proprietary algorithm-driven drug discovery platform has overcome these challenges to successfully identify a series of novel RyR2 modulators. This collaboration will include the modeling of all aspects of small molecule drug discovery, leveraging all available chemical and biological data and using Numerate’s AI-driven process to accelerate the path to the clinical phase.

“We are very pleased to be working with Servier, a global leader in cardiovascular medicine,” said Guido Lanza, President and CEO of Numerate. “Their long-standing appreciation for the complexity and the promise of this target made the power of our approach and the success we were having with our internal discovery program appealing. Our agreement forges an ideal combination of capabilities and expertise to advance these assets.”

“Numerate’s platform has literally cracked the code on rapidly identifying diverse, potent, and functionally active modulators of the ryanodine receptor,” said Dr. Isabelle Tupinon-Mathieu, Vice President of Research and Development and Head of Cardiovascular and Metabolism Therapeutic Innovation Poles. “This collaboration will also integrate with our ongoing and very productive partnership with Professor Andrew Marks and ARMGO, and accelerate the design of novel molecules to advance our cardiovascular program toward clinical development.”

Under the agreement, Servier has licensed Numerate’s RyR2 program including the novel compounds it identified. Numerate will also support efforts in assay development, lead design and optimization. Financial terms of the agreement were not disclosed.

About Servier

Servier is an international pharmaceutical company governed by a non-profit foundation with its headquarters based in Suresnes (France). With a strong international presence in 148 countries and a turnover of 4 billion euros in 2016, Servier employs 21,000 people worldwide. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular diseases, diabetes, cancers, immune-inflammatory diseases, and neurodegenerative diseases, as well as by its activities in high-quality generic drugs. Being completely independent, the Group reinvests 25% of turnover (excluding generics) in research and development and uses all its profits for growth. A key player in cardiology and hypertension for the last 20 years, Servier has 12 major products on the market with a total turnover of more than 1.6 billion euro in 2016. Currently, there are 12 new fixed-dose combinations and 10 new molecular entities in research or development, mainly targeting heart failure. This portfolio of innovative treatments is being developed with partners worldwide. For more information, visit www.servier.com.